Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,783.98
(
0.70%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 110117

Monday, 11/30/2015 11:03:31 AM

Monday, November 30, 2015 11:03:31 AM

Post# of 257302
BMY/ABBV—FDA approves Empliciti (elotuzumab) for second-third-fourth-line MM in combination with Revlimid and dexamethasone:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm

ABBV (then ABT) acquired Empliciti in its 2010 buyout of Facet Biotech (the successor company to PDLI) (#msg-47606240); BMY partnered with PDLI in 2008.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today